MediWound Ltd. (NASDAQ:MDWD) Receives $31.67 Average Price Target from Brokerages

MediWound Ltd. (NASDAQ:MDWD) has received an average rating of “Hold” from the five analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $31.6667.

MDWD has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a report on Thursday, January 22nd. Wall Street Zen cut MediWound from a “hold” rating to a “strong sell” rating in a research note on Saturday, March 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective (up from $31.00) on shares of MediWound in a report on Friday, November 21st.

MediWound Stock Performance

NASDAQ:MDWD opened at $16.58 on Monday. The company has a market capitalization of $212.39 million, a price-to-earnings ratio of -7.90 and a beta of 0.13. MediWound has a one year low of $14.14 and a one year high of $22.50. The stock has a 50-day simple moving average of $17.56 and a 200 day simple moving average of $17.85.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Thursday, March 5th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.09. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%.The firm had revenue of $1.87 million for the quarter, compared to analysts’ expectations of $2.09 million. On average, equities research analysts forecast that MediWound will post -2.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Rosalind Advisors Inc. grew its position in shares of MediWound by 84.0% during the 3rd quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock valued at $13,498,000 after buying an additional 341,993 shares during the last quarter. Kotler Kevin bought a new position in MediWound in the fourth quarter worth about $6,225,000. Meitav Investment House Ltd. boosted its stake in MediWound by 825.7% in the third quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock valued at $5,241,000 after acquiring an additional 260,116 shares during the period. Sphera Funds Management LTD. boosted its stake in MediWound by 24.3% in the fourth quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock valued at $4,252,000 after acquiring an additional 45,077 shares during the period. Finally, Silverberg Bernstein Capital Management LLC grew its holdings in shares of MediWound by 6.4% during the fourth quarter. Silverberg Bernstein Capital Management LLC now owns 183,924 shares of the biopharmaceutical company’s stock valued at $3,395,000 after purchasing an additional 11,108 shares during the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.